

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Subhashis Banerjee et al.

Serial No.: 10/623,035

ART UNIT: 1643

Filed: July 18, 2003

EXAMINER: David J. Blanchard

Entitled: : TREATMENT OF PAIN USING
TNFALPHA INHIBITORS

Attorney Docket No.: BBC-206

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

December 5, 2005

Date

Daphne Miller

Daphne Miller

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir/Madam:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 for the above-identified application. Applicants makes the following publications of record in the above-identified application.

U.S. Patent Documents

Salfeld et al., July 18, 2000, U.S. Patent No. 6,090,382

Salfeld et al., July 10, 2001, U.S. Patent No. 6,258,562

Salfeld et al., January 21, 2003, U.S. Patent No. 6,509,015

Foreign Patent Documents

Kempeni et al., December 19, 2002, WO 02/100330
Fischkoff et al., January 15, 2004, WO 2004/004633
Krause et al., February 26, 2004, WO 2004/016286
Kaymakcalan et al., May 6, 2004, WO 2004/037205
Salfeld et al., August 14, 1997, WO 97/29131

Other Publications

Aloe et al., *Psychopharmacology (Berl)*. 1997 Dec; 134(3): 287-292.
Bennett and Xie, (1988) *Pain*. 33: 87-107.
Coelho et al., *Am J Physiol Gastrointest Liver Physiol*. 2000 Oct; 279(4): G781-G790.
Coelho et al., *Brain Res Bull*. 2000 Jun; 52(3): 223-228.
Cunha et al., *Br J Pharmacol*. 1992 Nov., 107(3): 660-664.
Empl et al., *Neurology*. 2001 May 22; 56(10): 1371-1377.
Huygen et al., *Mediators Inflamm*. 2002 Feb;11(1): 47-51.
Ignatowski et al., *Brain Res*. 1999 Sep 11; 841(1-2): 70-77.
Kim and Chung, (1992) *Pain* 50: 355-363
Lindenlaub and Sommer (2003) *Acta Neuropathol (Berl)*. 105:593
Lindenlaub et al., *Brain Res*. 2000 Jun 2; 866(1-2): 15-22.
Myers, *Regional Anesthesia* (1995) 20:173-184
Old, L. *Science* (1985) 230: 630-632
Olmarker et al., *Spine*. 2001 Apr 15; 26(8): 863-869.
Parada et al., *Eur J Neurosci*. 2003 May; 17(9): 1847-1852.
Sagara et al., *Diabetologia*. 1996 Mar; 39(3): 263-269.
Schafers et al., *Neurosci Lett*. 2001 Sep 14; 310(2-3): 113-116.
Schafers et al., *J Neurosci*. 2003 Apr 1; 23(7): 3028-3038.
Sommer et al., *Brain Res*. 2001 Sep 14; 913(1): 86-89.
Sommer et al., *J Peripher Nerv Syst*. 2001 Jun; 6(2): 67-72.
Sommer et al., *Exp Neurol*. 1998 May; 151(1):138-142.
Sommer, C., *Schmerz* (1999) 13(5): 315-23.
Sorkin et al., *Neuroscience*. 1997 Nov; 81(1): 255-262.
Watkins et al., *Brain Res*. 1994 Aug 15; 654(1): 15-26.
Zimmermann, *Eur J Pharmacol*. 2001 Oct 19; 429(1-3): 23-37.

Form PTO-1449 listing each of these documents and photocopies of each document are enclosed herewith for the Examiner's convenience.

This paper is being mailed before the mailing of a first Office action. Pursuant to 37 CFR §1.97(b)(4), no fee is required with this submission.


Applicant does not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,



Tara Seshadri, Ph.D.
Agent for Applicant
Registration No. 48,591
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605-4314
Telephone: (508) 688-8058
Telefax: (508) 688-8110



DEC 19 2005

PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/623,035
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-206

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	4	WO 02/100330	12-19-2002	Abbott Biotechnology Ltd.		
	5	WO 04/004633	01-15-2004	Abbott Biotechnology Ltd.		
	6	WO 04/016286	02-26-2004	Abbott Biotechnology Ltd.		
	7	WO 04/037205	05-06-2004	Abbott Biotechnology Ltd.		
	8	WO 97/29131	08-14-1997	BASF Aktiengesellschaft		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/623,035
		Filing Date	July 18, 2003
		First Named Inventor	S. Banerjee
		Art Unit	1643
Sheet 2 of 4	Examiner Name	David J. Blanchard	
Sheet 2 of 4	Attorney Docket Number	BBC-206	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Aloe et al., "Role of TNF-alpha but not NGF in murine hyperalgesia induced by parasitic infection". <i>Psychopharmacology (Berl)</i> . 1997 Dec; 134(3): 287-292.	
		Bennett and Xie, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man". (1988) <i>Pain</i> . 33: 87-107.	
		Coelho et al., "Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve". <i>Am J Physiol Gastrointest Liver Physiol</i> . 2000 Oct; 279(4): G781-G790.	
		Coelho et al., "Brain interleukin-1 β and tumor necrosis factor- α are involved in lipopolysaccharide-induced delayed rectal allodynia in awake rats". <i>Brain Res Bull</i> 2000 June, 52(3): 223-228.	
		Cunha et al., "The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia." <i>Br J Pharmacol</i> . 1992 Nov., 107(3): 660-664.	
		Empl et al., <i>Neurology</i> . "TNF-alpha expression in painful and nonpainful neuropathies." 2001 May 22; 56(10): 1371-1377.	
		Huygen et al., "Evidence for local inflammation in complex regional pain syndrome type 1." <i>Mediators Inflamm</i> . 2002 Feb;11(1): 47-51.	
		Ignatowski et al., "Brain-derived TNFalpha mediates neuropathic pain." <i>Brain Res</i> . 1999 Sep 11; 841(1-2): 70-77.	
		Kim and Chung, "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat." (1992) <i>Pain</i> 50: 355-363	
		Lindenlaub and Sommer, "Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies." (2003) <i>Acta Neuropathol (Berl)</i> . 105:593	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3

of 4

Complete if Known	
Application Number	10/623,035
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-206

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lindenlaub et al., "Effects of neutralizing antibodies to TNFalpha on pain-related behavior and nerve regeneration in mice with chronic constriction injury." Brain Res. 2000 Jun 2; 866(1-2): 15-22.	
		Myers, R., "The Pathogenesis of Neuropathic Pain." Regional Anesthesia (1995) 20(3):173-184.	
		Old, L., "Tumor Necrosis Factor (TNF)." (1985) Science 230: 630-632	
		Olmarker et al., "Selective Inhibition of Tumor Necrosis Factor-alpha Prevents Nucleus Pulsus-Induced Thrombus Formation, Intranerve Edema, and Reduction of Nerve Conduction Velocity." Spine. 2001 Apr 15; 26(8): 863-869.	
		Parada et al., "Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat." Eur J Neurosci. 2003 May; 17(9): 1847-1852.	
		Sagara et al., "Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine." Diabetologia. 1996 Mar; 39(3): 263-269.	
		Schafers et al., "Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice." Neurosci Lett. 2001 Sep 14; 310(2-3): 113-116.	
		Schafers et al., "Increased Sensitivity of Injured and Adjacent Uninjured Rat Primary Sensory Neurons to Exogenous Tumor Necrosis Factor after Spinal Nerve Ligation J Neurosci. 2003 Apr 1; 23(7): 3028-3038.	
		Sommer et al., "Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy." Brain Res. 2001 Sep 14; 913(1): 86-89.	
		Sommer et al., "Etanercept reduces hyperalgesia in experimental painful neuropathy." J Peripher Nerv Syst. 2001 Jun; 6(2): 67-72.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/623,035
		Filing Date	July 18, 2003
		First Named Inventor	S. Banerjee
		Art Unit	1643
		Examiner Name	David J. Blanchard
Sheet 4	of 4	Attorney Docket Number	BBC-206

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sommer et al., "Hyperalgesia in Experimental Neuropathy Is Dependent on the TNF Receptor 1." <i>Exp Neurol.</i> 1998 May; 151(1):138-142	
		Sommer, C. "Animal studies on neuropathic pain: the role of cytokines and cytokine receptors in pathogenesis and therapy." <i>Schmerz.</i> (1999) 13(5): 315-323.	
		Sorkin et al., "Tumour necrosis factor-alpha induces extopic activity in nociceptive primary afferent fibres." <i>Neuroscience.</i> 1997 Nov; 81(1): 255-262.	
		Watkins et al., "Characterization of cytokine-induced hyperalgesia." <i>Brain Res.</i> 1994 Aug 15; 654(1): 15-26.	
		Zimmermann, "Pathobiology of neuropathic pain." <i>Eur J Pharmacol.</i> 2001 Oct 19; 429(1-3): 23-37.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.